Alnylam Pharmaceuticals, Inc.
ALNY
Rang în acțiuni
#788
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily... Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Preț acțiune
$230.76
Capitalizare de piață
$30.88B
Schimbare (1 zi)
-1.08%
Schimbare (1 an)
-53.02%
Țară
US
Tranzacționează Alnylam Pharmaceuticals, Inc. (ALNY)
Categorie
Healthcare
Câștiguri pentru Alnylam Pharmaceuticals, Inc. (ALNY)
Câștiguri în Jun 2026 TTM: $799.57M
Conform celor mai recente rapoarte financiare ale Alnylam Pharmaceuticals, Inc., câștigurile actuale ale companiei sunt $799.57M. În anul 2024, compania a înregistrat un câștig de $-377.38M, o creștere față de câștigului din 2023, care a fost de $-433.52M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Alnylam Pharmaceuticals, Inc. din 2002 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $799.57M | 147.43% |
| 2025 | $323.15M | -185.63% |
| 2024 | $-377.38M | -12.95% |
| 2023 | $-433.52M | -61.53% |
| 2022 | $-1.13B | 32.25% |
| 2021 | $-852.14M | -0.40% |
| 2020 | $-855.60M | -3.35% |
| 2019 | $-885.25M | 16.38% |
| 2018 | $-760.67M | 54.96% |
| 2017 | $-490.87M | 19.69% |
| 2016 | $-410.11M | 41.38% |
| 2015 | $-290.07M | -27.59% |
| 2014 | $-400.60M | 335.82% |
| 2013 | $-91.92M | -21.16% |
| 2012 | $-116.59M | 102.23% |
| 2011 | $-57.65M | 34.06% |
| 2010 | $-43.00M | -8.52% |
| 2009 | $-47.01M | 84.13% |
| 2008 | $-25.53M | -68.18% |
| 2007 | $-80.22M | 131.80% |
| 2006 | $-34.61M | -19.35% |
| 2005 | $-42.91M | 21.34% |
| 2004 | $-35.37M | 19.10% |
| 2003 | $-29.69M | 0.00% |
| 2002 | 0.00 | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $5.27B | 559.72% |
US
|
|
| $-3.09B | -486.08% |
US
|
|
| $-4.02B | -602.30% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 143.96% |
NL
|
